Prof Chris Ormandy
Principal Research Fellow
Prof Chris Ormandy completed his undergraduate studies at the University of Sydney in 1984 and his PhD at the University of New South Wales in 1992.
In 2003 Chris was the NHMRC CJ Martin Fellow at Institut Necker and Institut Pasteur Paris. In 2006 he moved back to Australia and was appointed as a senior scientist at the Kolling Institute, Royal North Shore Hospital. In 2007 Chris joined the Garvan Institute of Medical research as a Research Group Leader.
Chris is currently President elect and board Member of the International Association for Breast Cancer Research, an Executive member of the Scientific Advisory Board of the National Breast Cancer Foundation Austraila and a National Health and Medical Research Council Research Fellow.
In the News
Awards and Honours
1984 - BSc (Hons), University of Sydney - Australia
Gallego-Ortega D, Oakes SR, and Ormandy CJ. Elf5 and breast cancer. Future Medicine Breast Cancer Management. 2013; 2:489-498
Lee, H.J., D. Gallego-Ortega, A. Ledger, D. Schramek, P. Joshi, M.M. Szwarc, C. Cho, J.P. Lydon, R. Khokha, J.M. Penninger, and C.J. Ormandy, Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development, 2013; 140(7):1397-1401.
Lee, H.J. and C.J. Ormandy, Elf5, hormones and cell fate. Trends in Endocrinology and Metabolism, 2012; 23(6):292-298.
Kalyuga, M., D. Gallego-Ortega, H.J. Lee, D.L. Roden, M.J. Cowley, C.E. Caldon, A. Stone, S.L. Allerdice, F. Valdes-Mora, R. Launchbury, A.L. Statham, N. Armstrong, M.C. Alles, A. Young, A. Egger, W. Au, C.L. Piggin, C.J. Evans, A. Ledger, T. Brummer, S.R. Oakes, W. Kaplan, J.M.W. Gee, R.I. Nicholson, R.L. Sutherland, A. Swarbrick, M.J. Naylor, S.J. Clark, J.S. Carroll, and C.J. Ormandy, ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer. Plos Biology, 2012;10(12): e1001461.
Lee, H.J., R.A. Hinshelwood, T. Bouras, D. Gallego-Ortega, F. Valdes-Mora, K. Blazek, J.E. Visvader, S.J. Clark, and C.J. Ormandy, Lineage Specific Methylation of the Elf5 Promoter in Mammary Epithelial Cells. Stem Cells, 2011; 29(10):1611-1619.
Alles, M.C., M. Gardiner-Garden, D.J. Nott, Y.X. Wang, J.A. Foekens, R.L. Sutherland, E.A. Musgrove, and C.J. Ormandy, Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the "Basal" Breast Cancer Subgroup. Plos One, 2009; 4(3):e4710.
Oakes, S.R., M.J. Naylor, M.L. Asselin-Labat, K.D. Blazek, M. Gardiner-Garden, H.N. Hilton, M. Kazlauskas, M.A. Pritchard, L.A. Chodosh, P.L. Pfeffer, G.J. Lindeman, J.E. Visvader, and C.J. Ormandy, The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes & Development, 2008; 22(5):581-586.
Oakes, S.R., F.G. Robertson, J.G. Kench, M. Gardiner-Garden, M.P. Wand, J.E. Green, and C.J. Ormandy, Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene, 2007; 26(4):543-553.
Harris, J., P.M. Stanford, K. Sutherland, S.R. Oakes, M.J. Naylor, F.G. Robertson, K.D. Blazek, M. Kazlauskas, H.N. Hilton, S. Wittlin, W.S. Alexander, G.J. Lindeman, J.E. Visvader, and C.J. Ormandy, Socs2 and Elf5 mediate prolactin-induced mammary gland development. Molecular Endocrinology, 2006; 20(5):1177-1187.
Naylor, M.J., E. Ginsburg, T.P. Iismaa, B.K. Vonderhaar, D. Wynick, and C.J. Ormandy, The neuropeptide galanin augments lobuloalveolar development. Journal of Biological Chemistry, 2003; 278(31):29145-29152.
Brisken, C., S. Kaur, T.E. Chavarria, N. Binart, R.L. Sutherland, R.A. Weinberg, P.A. Kelly, and C.J. Ormandy, Prolactin controls mammary gland development via direct and indirect mechanisms. Developmental Biology, 1999; 210(1):96-106.
Ormandy, C.J., A. Camus, J. Barra, J.D. Damotte, B. Lucas, H. Buteau, M. Edery, N. Brousse, C. Babinet, N. Binart, and P.A. Kelly, Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes & Development, 1997; 11(2):167-178.